Description

Abciximab 10mg amp
abciximab, un antagonista del receptor de glicoproteína IIb/IIIa fabricado por Janssen Biologics BV y distribuido por Eli Lilly con el nombre comercial ReoPro, es un inhibidor de la agregación plaquetaria que se utiliza principalmente durante y después de procedimientos de arterias coronarias como la angioplastia para evitar que las plaquetas se peguen y provoquen la formación de trombos. dentro de la arteria coronaria.

Precios de marca REOPRO: U$D 1,577.00
Nuestro precio genérico: U$D $155.00

Abciximab
abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus formation within the coronary artery.

Background
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.